Neogenomics INC Schedule 13G passive stakes

BlackRock, Inc. has reported a beneficial ownership of 20,358,331 shares, representing 15.6% of the common stock of NeoGenomics Inc., as of June 30, 2026.

First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation have jointly filed a Schedule 13G, reporting beneficial ownership of 10,113,261 shares, representing 7.77% of NeoGenomics, Inc. common stock.

Greenhouse Funds LLLP and associated parties have filed an amendment reporting a 7.1% beneficial ownership stake in NeoGenomics, Inc.

Millennium Management LLC and Israel A. Englander have filed a Schedule 13G reporting a 1.7% beneficial ownership stake in NeoGenomics, Inc.

First Light Asset Management, LLC and Mathew P. Arens have jointly filed a Schedule 13G, reporting beneficial ownership of over 10% of Neogenomics, Inc. common stock as of April 30, 2026.

Vanguard Capital Management reports beneficial ownership of over 6.6 million shares, representing 5.09% of NeoGenomics Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 7,677,794 shares, representing 5.91% of NeoGenomics Inc.'s common stock as of March 31, 2026.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported a 5.0% beneficial ownership stake in NeoGenomics, Inc.

Millennium Management LLC and affiliates reported beneficial ownership of 4.97% of NeoGenomics, Inc. common stock, having previously exceeded 5%.

BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G, reporting a 14.6% beneficial ownership stake in NeoGenomics Inc. as of September 30, 2025.

First Light Asset Management, LLC and its principal, Mathew P. Arens, disclosed significant beneficial ownership in Neogenomics, Inc., holding 7.57% of common stock.

Greenhouse Funds LLLP and its affiliates have disclosed a 5.8% passive ownership stake in cancer diagnostics firm NeoGenomics, Inc.

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, reporting a collective passive beneficial ownership of up to 2.8% of NeoGenomics, Inc.'s common stock as of June 30, 2025.

T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G, reporting a 2.6% beneficial ownership stake in NeoGenomics Inc. as of March 31, 2025.

Millennium Management LLC, along with its affiliates Integrated Core Strategies (US) LLC, Millennium Group Management LLC, and Israel A. Englander, have disclosed a passive beneficial ownership of 5.4% in NeoGenomics, Inc.'s common stock.

Janus Henderson Group PLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 4.8% in NeoGenomics Inc. as of December 31, 2024.